Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

ith other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

On site at ESC in Munich

Natacha Gassenbach

(508) 250-9348 (mobile)

Media Relations

Boston Scientific

Geraldine Varoqui'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Group (USA), Inc. (the "Company" or "Tiens", NYSE AMEX: ... announced financial results for the third quarter and nine months ... of 2010 was $10.4 million, compared to $9.4 million for the ... 30, 2010 was $30.0 million, compared to $48.2 million for the ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
... Webcast to Discuss ASSERT Clinical Trial Data ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 2Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 3Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 5Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 6Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 7
(Date:7/30/2014)... ALBANY, New York , July 30, 2014 ... up-to-date research on Global Government Biometric Systems ... Analysis. The Global Biometric Systems Market ... global biometric systems market over the next ten ... industry, using detailed market size forecasts. ...
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... interest in neuroscience. A large number of genes ... Wallerian degeneration: transcription factor activation, immune response, myelin ... in the distal segment of the sciatic nerve ... gene expression between the proximal and distal segments ... Nantong University, China used microarrays to analyze changes ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... trauma, say from a sabertooth tiger attack, meant immediate death ... to survive severe injury caused by a car crash, gunshot ... does not know what to do when it survives an ... evolution. Nearly one third of the time, mechanisms in place ...
... that the ability of plants to defend themselves by accumulating ... some insects, and that such adaptation potentially echoes in the ... evolve to deal with high levels of the toxic element. ... and colleagues there and at the University of California, Berkeley, ...
... and proteins that explain how animals discern bitter from sweet, ... mutant fruit flies prefer eating sugar over sugar laced with ... that a single protein missing from the fly-equivalent of our ... the caffeine as if it were not there. , "No, ...
Cached Biology News:PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 3
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
...
... the revolutionary Luminex 100 System delivers a ... real time enhancing your operational efficiency. This ... Luminex 100, the XY Platform, and the ... you to simultaneously assay up to 100 ...
Biology Products: